Cargando…
T cell receptor-engineered T cells for leukemia immunotherapy
At present, refractory and relapse are major issues for leukemia therapy and a major cause of allogeneic hematopoietic stem cell transplant failure. Over the last decade, many studies have demonstrated that adoptive cancer antigen-specific T cell therapy is an effective option for leukemia therapy....
Autores principales: | Zhang, Yikai, Li, Yangqiu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317187/ https://www.ncbi.nlm.nih.gov/pubmed/30622438 http://dx.doi.org/10.1186/s12935-018-0720-y |
Ejemplares similares
-
TCR engineered T cells for solid tumor immunotherapy
por: Zhang, Yikai, et al.
Publicado: (2022) -
The role of peptide and DNA vaccines in myeloid leukemia immunotherapy
por: Lin, Chen, et al.
Publicado: (2013) -
New insights into antigen specific immunotherapy for chronic myeloid leukemia
por: Li, Yangqiu, et al.
Publicado: (2012) -
The roles of stem cell memory T cells in hematological malignancies
por: Xu, Ling, et al.
Publicado: (2015) -
Trial Watch: Adoptive TCR-Engineered T-Cell Immunotherapy for Acute Myeloid Leukemia
por: Campillo-Davo, Diana, et al.
Publicado: (2021)